<![CDATA[FDA Rejects Rivoceranib/Camrelizumab in First-Line Unresectable HCC]]>
Read the full articleYou might also wanna read
HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss
First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
Conditions : Unresectable Hepatocellular Carcinoma Interventions : Combination Product: Nivolumab plus ipilimumab Sponsors : Bristol-Myers S
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Conditions : Liver Cancer Interventions : Device: DEB-TACE; Drug: Toripalimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin Sponso
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
Conditions : Hepatocellular Carcinoma Interventions : Drug: SHR-8068+ Adebrelimab+ Bevacizumab; Drug: SHR-8068 Placebo+ Adebrelimab Placebo+
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Conditions : Hepatocellular Carcinoma (HCC) Interventions : Drug: Nivolumab; Drug: Ipilimumab (3 mg/kg) Sponsors : University of Texas South
A Study of Combination Therapy in Patients With Resectable Liver Cancer
Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl
Comments
Sign in to join the conversation.
No comments yet. Be the first.